Comparison of Color Vision in Patients with Multiple Sclerosis

Document Type : Original Article

Authors

1 Department of optometry, Iran University of Medical Sciences, Tehran, Iran

2 Department of Occupational Therapy, University of Medical Sciences, Tehran, Iran

3 Department of Medicine, Shahed University of Medical Sciences, Tehran, Iran

4 Department of Optometry, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran

5 Department of Optometry, School of Medical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran

6 Noor Research Center for Ophthalmic Epidemiology, Noor Eye Hospital, Tehran, Iran

Abstract

Purpose:
This study aimed to quantitatively assess the color vision in patients with relapsing and remitting multiple sclerosis with and without visual symptoms using D15.
Methods:
In this study, 100 eyes of 50 patients with Multiple Sclerosis including 30 patients with visual symptoms and 20 patients without visual symptoms were compared with 50 eyes as the control group. Patients were divided into 4 groups: An involved eye of the patient with unilateral visual symptoms (group 1), fellow eye of the patient with unilateral visual symptoms (group 2), patient’s eye without visual symptoms (group 3), and eyes of the comparison group (group 4). Visual acuity was measured in log MAR. Color vision was evaluated using D15. The results were quantitatively recorded based on Color Confusion Index (CCI).
Results:
The meanCCI of color vision was 131.17±19.69 in the first group, 126.39±15.31 in the second group, 123.62±10.03 in the third group, and 117 in the fourth group. There was a significant difference between three groups and the control group. (p<0.0001, pConclusion:
Color vision disorder has been observed in patients with and without visual symptoms; however, the severity of the defect was different between groups. Quantitative assessment of the color vision test provides useful information of the natural history of the disease for examiner. In addition, there are appropriate clinical criteria to identify subclinical defects along with other diagnostic methods in patients with MS.

Keywords

Main Subjects

References

  1. Calabresi, P.A., Diagnosis and management of multiple sclerosis. Am Fam Physician 2004; 70(10): 1935-44.
  2. Frohman, E.M., Frohman T.C, Zee D.S, McColl R, et al., The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4(2): 111-21.
  3. Gundogan, F.C.,Tas A, Altun S, Oz O, et al., Color vision versus pattern visual evoked potentials in the assessment of subclinical optic pathway involvement in multiple sclerosis. Indian J Ophthalmol 2013; 61(3): 100-3.
  4. Shaygannejad, V.,Gholabchi K, Dehghani A, Ashtari F, et al., Color blindness among multiple sclerosis patients in Isfahan. J Res Med Sci 2012; 17(3): 254-7.
  5. Menage, M.J.,Papakostopoulos D, Dean Hart JC, Papakostopoulos S, et al., The Farnsworth-Munsell 100 hue test in the first episode of demyelinating optic neuritis. Br J Ophthalmol 1993; 77(2): 68-74.
  6. Hoyt, C.S. The Farnsworth-Munsell 100 hue test and optic neuritis. Br J Ophthalmol 1993; 77(2): 65.
  7. Schneck, M.E. and G. Haegerstrom-Portnoy. Color vision defect type and spatial vision in the optic neuritis treatment trial. Invest Ophthalmol Vis Sci 1997; 38(11): 2278-89.
  8. Katz, B., The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial. Trans Am Ophthalmol Soc 1995; 93: 685-708.
  9. Travis, D. and P. Thompson, Spatiotemporal contrast sensitivity and colour vision in multiple sclerosis. Brain 1989; 112 ( Pt 2): 283-303.
  10. Flanagan, P. and A.J. Zele, Chromatic and luminance losses with multiple sclerosis and optic neuritis measured using dynamic random luminance contrast noise. Ophthalmic Physiol Opt 2004; 24(3): 225-33.
  11. Frederiksen, J., Larsson H, Olesen J, Stigsby B. Evaluation of the visual system in multiple sclerosis. II. Colour vision. Acta Neurol Scand 1986; 74(3): 203-9.
  12. Frederiksen, J.L, Larsson H.B, Ottovay E, Stigsby B, et al., Acute optic neuritis with normal visual acuity. Comparison of symptoms and signs with psychophysiological, electro- physiological and magnetic resonance imaging data. Acta Ophthalmol (Copenh) 1991; 69(3): 357-66.
  13. Sartucci, F., Murri L, Orsini C, Porciatti V , Equiluminant red-green and blue-yellow VEPs in multiple sclerosis. J Clin Neurophysiol 2001; 18(6): 583-91.
  14. Jackson, T.L., G.L. Ong, and L.G. Ripley, Orientational contrast sensitivity and chromatic contrast thresholds in multiple sclerosis. Am J Ophthalmol 2004; 137(2): 283-6.
  15. Moura, A.L, Teixeira R.A, Oiwa N.N, Costa M.F, et al., Chromatic discrimination losses in multiple sclerosis patients with and without optic neuritis using the Cambridge Colour Test. Vis Neurosci 2008; 25(3): 463-8.
  16. Benjamin, W.J. and I.M. Borish, Borish's Clinical Refraction. 2006: Butterworth-Heinemann.Chapter 9.
  17. Bowman, K.J. A method for quantitative scoring of the Farnsworth Panel D-15. Acta Ophthalmol (Copenh) 1982; 60(6): 907-16.
  18. Beck, R.W.,Kupersmith M.J, Cleary P.A, Katz B, et al., Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial. Ophthalmology 1993; 100(5):691-7; discussion 697-8.

Journal of Paramedical Sciences & Rehabilitation
Volume 7, Issue 2
May 2018
Pages 37-42

Files

Share

How to cite

Statistics